Építés alatt – nem éles oldal
Belépés
Leállítva4. fázis

Trial of Naproxen Sodium for the Treatment of OCD in Children With PANDAS

A legfontosabb adatok

Ki végzi
Massachusetts General Hospital
Hol
Boston (Egyesült Államok)A helyszín megnézése
Azonosító
Állapot
Leállítva
Fázis
4. fázis
Résztvevők
2 fő vett részt
Kezdés
2020. okt. 20.
Befejezés
2025. ápr. 30.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
A vizsgált kezelések
  • Naproxen Sodium
  • Placebo
A regiszteradat frissítve
2026. május 20.
Miért állt le
Low recruitment

Ki vehet részt

Életkor
6 év – 15 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 29 feltétel megnézéseKevesebb

Ki vehet részt

  • significantly interfering Obsessive-Compulsive Disorder (OCD) symptoms
  • ages 6- to 15-years-old
  • new-onset of OCD symptoms within the previous 18 months
  • sufficient fluency of English to understand study staff, procedures and questionnaires,
  • able to take medication in pill form
  • parent/legal guardian who can provide informed consent; Patients must also meet all criteria for PANDAS, which are:
  • prepubertal symptom onset
  • acute onset of symptoms (from no/minimal symptoms to maximum severity within 24-48 hours) and/or an episodic (relapsing-remitting) course
  • temporal association between symptomatic periods and infections with Group A Streptococcus (GAS) infection
  • presence of neurological abnormalities (e.g. handwriting deterioration, choreiform movements); The onset/exacerbation of OCD symptoms must also be accompanied by at least three of the following clinical signs and symptoms, including:
  • Markedly increased level of anxiety, particularly new onset of separation anxiety
  • Emotional lability, irritability, aggressive behavior and/or personality change
  • Sudden difficulties with concentration or learning
  • Developmental regression ("baby-talk", temper tantrums)
  • Sleep disorder (insomnia, night terrors, refusal to sleep alone)
  • Handwriting deterioration or other sign of motoric dysfunction (including new onset of motor hyperactivity, presence of choreiform finger movements, pronator drift or truncal instability)
  • Urinary frequency or increased urge to urinate; daytime or night-time secondary enuresis; These co-occurring symptoms must be "severe" or "dramatic" and proceed from no/minimal symptoms to maximum severity within the same 24-48 hour interval during which the OCD symptoms arose. In addition to these inclusion criteria, PANDAS subjects will be required to provide documentation of a positive GAS infection via medical records. As the time between a documented GAS infection and the onset of PANDAS symptoms has not been defined in the PANDAS diagnostic criteria, the investigators will use a guideline of approximately six weeks or less between a documented GAS infection and the onset of OCD symptoms for inclusion into the study

Ki nem vehet részt

  • concurrent antibiotic treatment or antibiotic treatment within one-week of baseline
  • concurrent selective serotonin reuptake inhibitor (SSRI) or other psychoactive medication treatment except and unless the dose has been stable for at least 6 weeks (i.e. no recent titration, initiation, or change in dosage)
  • concurrent medications that do not meet the above criteria (e.g., other psychotropic medications or anti-inflammatory agents)
  • child has a serious neurological disorder or impairment (e.g. brain damage, blindness, deafness), an intellectual disability, or autism
  • history of immune modulating therapies for OCD/PANDAS symptoms
  • history of ulcers in the digestive system
  • history of restricted fluid intake, as this could exacerbate side effects
  • history of severe asthma or currently uncontrolled asthma
  • pre-existing liver, kidney, GI bleeding or clotting disorders (GFR <75 mL/min/1.73m2)
  • child who is acutely psychotic or suicidal
  • pregnant or becomes pregnant
  • currently engaged in an intensive outpatient cognitive behavioral treatment program (more than weekly)

Helyszínek itt: Egyesült Államok

  • Massachusetts General HospitalBoston, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

This project aims to rigorously evaluate a potential treatment for inflammation-related Obsessive-Compulsive Disorder (OCD) symptoms in children. To accomplish this goal, the investigators will conduct a double-blind, randomized, placebo-controlled trial of Naproxen Sodium, a nonsteroidal anti-inflammatory drug (NSAID) in participants diagnosed with Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcal infections (PANDAS). This research fills a gap in the empirical evidence base for the treatment of PANDAS, and will add to a growing literature of empirically-derived practices for PANDAS.

A vizsgálat 2 csoportja

  • InterventionA vizsgált kezelés

    Participants receive Naproxen Sodium.

    Kezelés: Naproxen Sodium

  • PlaceboPlacebo, összehasonlításként

    Participants receive placebo.

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Double-Blind, Randomized, Placebo-Controlled Trial of Naproxen Sodium for the Treatment of Obsessive Compulsive Symptoms in Pediatric Autoimmune Neuropsychiatric Disorder Associated With Streptococcal Infections (PANDAS)
A regiszteradat frissítve
2026. május 20.